ProCE Banner Activity

CE / CME

Addressing Treatment Challenges in Growth Hormone Deficiency With Novel Long-Acting Therapies

Video

Experts provide insight for endocrinology specialists to address the treatment challenges in growth hormone deficiency. Esteemed faculty will discuss the available and emerging treatment options in pediatric and adult patients as well as providing insights in overcoming challenges with long-term GHD management.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: August 04, 2023

Expiration: August 03, 2024

No longer available for credit.

Share

Faculty

Sara Divall

Sara Divall, MD

Associate Professor, Pediatrics
Center for Clinical and Translational Research
Endocrinology Fellowship Director
Seattle Children’s Endocrinology
University of Washington Medicine
Seattle, Washington

Andrew Hoffman

Andrew Hoffman, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, California

Laurence Katznelson

Laurence Katznelson, MD

Professor of Medicine (Endocrinology) and Neurosurgery
Associate Dean of Graduate Medical Education
Medical Director, Pituitary Center
Stanford Health Care, Stanford School of Medicine
Stanford, California

Provided by

Jointly provided by Clinical Care Options, LLC and Endocrine Society

ProCE Banner
ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

This program is intended for adult and pediatric endocrinology specialists (MDs, NPs, PAs), primary care/family medicine providers (MDs, NPs, PAs), scientists, researchers, and other healthcare professionals who manage adult and pediatric patients with growth hormone deficiency. 

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners to improve the timely diagnosis and optimize treatment for patients with growth hormone deficiency.

Learning Objectives

  • Apply the appropriate diagnostic tests to a patient with a high suspicion of GHD

  • Evaluate the efficacy and safety of long-acting growth hormone therapies in pediatric and adult patients with GHD

  • Develop comprehensive treatment plans for patients with GHD, including agent selection, dosing, and monitoring

  • Implement strategies to improve treatment adherence and transitions of care for patients with GHD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Sara Divall, MD

Associate Professor, Pediatrics
Center for Clinical and Translational Research
Endocrinology Fellowship Director
Seattle Children’s Endocrinology
University of Washington Medicine
Seattle, Washington

Sara DiVall, MD: has no relevant financial relationships to disclose.

Andrew Hoffman, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, California

Andrew Hoffman, MD: consultant/advisor/speaker: Ascendis, Novo Nordisk. 

Laurence Katznelson, MD

Professor of Medicine (Endocrinology) and Neurosurgery
Associate Dean of Graduate Medical Education
Medical Director, Pituitary Center
Stanford Health Care, Stanford School of Medicine
Stanford, California

Laurence Katznelson, MD: consultant/advisor/speaker: Novo Nordisk, Recordati, Pfizer, Stonebridge; researcher: Camarus, Novartis.

The planners and content peer reviewers from Clinical Care Options, LLC and Endocrine Society do not have any relevant financial relationships to disclose, except Amy Butts, PA-C as noted below:

Amy Butts, PA-C: consultant/advisor/speaker: Abbott, Bayer, Novo Nordisk, Sanofi.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit

The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate/Physician Assistant Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until August 03, 2024. PAs should only claim credit commensurate with the extent of their participation.